The prevalence of ICBs in patients treated with apomorphine infusion: a retrospective analysis
Objective: To assess the prevalence of impulsive compulsive behaviours (ICBs) in Parkinson’s disease who donated their brains and used apomorphine infusion in life. Background: Impulsive…Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study
Objective: To compare time to onset and magnitude of motor improvement following administration of apomorphine sublingual film (APL-130277; APL) vs levodopa in patients with Parkinson’s…The Power of Normal Saline in Reducing Skin Nodules in Apomorphine
Objective: This is a poster presentation Background: Continuous apomorphine therapy is a pump delivered infusion via subcutaneous injection for management of advanced therapy in Parkinson's…Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease
Objective: To describe correlations of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores with the 39-item Parkinson’s disease (PD) questionnaire…The long-term effect of continuous apomorphine treatment on camptocormia in Parkinson´s disease: a 24-months longitudinal open, prospective follow-up study
Objective: The aim of the study was to assess the long-term effect of subcutaneous infusions of apomorphine in the treatment of camptocormia in advanced Parkinson's…Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study
Objective: To evaluate the long-term efficacy of APO in PD patients treated at two specialist centres in Spain and Thailand, and to determine the reasons…Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease
Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study
Objective: To evaluate the long-term safety and efficacy of apomorphine infusion (APO) in PD patients with motor fluctuations despite optimised oral therapy. Background: The randomised,…Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis
Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions
Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »